Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

MLA

Gelderblom, Hans, et al. “Vimseltinib versus Placebo for Tenosynovial Giant Cell Tumour (MOTION): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet, vol. 403, no. 10445, June 2024, pp. 2709–19. EBSCOhost, https://doi.org/10.1016/S0140-6736(24)00885-7.

APA

Gelderblom, H., Bhadri, V., Stacchiotti, S., Bauer, S., Wagner, A. J., van de Sande, M., Bernthal, N. M., López Pousa, A., Razak, A. A., Italiano, A., Ahmed, M., Le Cesne, A., Tinoco, G., Boye, K., Martín-Broto, J., Palmerini, E., Tafuto, S., Pratap, S., Powers, B. C., … Ravi, V. (2024). Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 403(10445), 2709–2719. https://doi.org/10.1016/S0140-6736(24)00885-7

Chicago

Gelderblom, Hans, Vivek Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J Wagner, Michiel van de Sande, Nicholas M Bernthal, et al. 2024. “Vimseltinib versus Placebo for Tenosynovial Giant Cell Tumour (MOTION): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet 403 (10445): 2709–19. doi:10.1016/S0140-6736(24)00885-7.